Seladelpar治疗原发性胆汁性胆管炎的真实世界经验
治疗1个月后56.3%患者达生化应答,31.3%患者碱性磷酸酶恢复正常。
要点
- 真实世界中seladelpar作为PBC二线治疗1个月生化应答率56.3%。
- 31.3%患者治疗后1个月碱性磷酸酶水平恢复正常。
- 18例中7例以seladelpar作为初始二线治疗,11例曾用其他二线药物。
核心结论
- 真实世界临床实践中seladelpar作为PBC二线治疗显示有效。
主要发现
- 治疗1个月后56.3%患者达生化应答,31.3%患者碱性磷酸酶水平恢复正常。
- 18例中11例曾接受其他二线治疗,7例以seladelpar作为初始二线治疗。
关键数值与推荐
- 生化应答率56.3%(治疗1个月,n=18)。
- 碱性磷酸酶恢复正常率31.3%(治疗1个月,n=18)。
临床怎么用
- seladelpar可作为PBC患者二线治疗选择,短期1个月可见生化改善。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Seladelpar recently received accelerated FDA approval for the treatment of primary biliary cholangitis (PBC) but there is limited knowledge regarding its efficacy in real-world clinical practice. This is a study of a cohort of adults with PBC who were started on seladelpar as second-line therapy between October 2024 and March 2025. Of the 18 patients, 11 were trialed on a second-line therapy prior to switching to seladelpar, whereas 7 of the patients started seladelpar as initial second-line therapy. Biochemical response was achieved in 56.3% of patients and normalisation of alkaline phosphatase levels in 31.3% of patients after 1 month of treatment. This study demonstrates the efficacy of seladelpar as a second-line agent in a real-world clinical setting.
引用
- Kuo SZ, Yin J, Loomba R, et al. Research Communication: Real-World Clinical Experience With Seladelpar in Primary Biliary Cholangitis. Aliment Pharmacol Ther. 2025. PMID: 41163419. doi:10.1111/apt.70435
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。